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Abstract
Background: An incomplete understanding of the immunological mechanisms underlying protection against
tuberculosis (TB) hampers the development of new vaccines against TB. We aimed to define host correlates of
prospective risk of TB disease following bacille Calmette–Guérin (BCG) vaccination.
Methods: In this study, 5,726 infants vaccinated with BCG at birth were enrolled. Host responses in blood collected
at 10 weeks of age were compared between infants who developed pulmonary TB disease during 2 years of
follow-up (cases) and those who remained healthy (controls).
Results: Comprehensive gene expression and cellular and soluble marker analysis failed to identify a correlate of
risk. We showed that distinct host responses after BCG vaccination may be the reason: two major clusters of gene
expression, with different myeloid and lymphoid activation and inflammatory patterns, were evident when all
infants were examined together. Cases from each cluster demonstrated distinct patterns of gene expression, which
were confirmed by cellular assays.
Conclusions: Distinct patterns of host responses to Mycobacterium bovis BCG suggest that novel TB vaccines may
also elicit distinct patterns of host responses. This diversity should be considered in future TB vaccine development.
Keywords: Tuberculosis, Vaccine, Correlates of risk, Systems biology
Background
Newborn vaccination with bacille Calmette–Guérin
(BCG) protects infants and young children against dis-
seminated forms of tuberculosis (TB), and to some ex-
tent, against pulmonary TB [1]. As BCG’s protective
efficacy in other age groups is variable and mostly poor
[1], new vaccines against TB are needed. An incomplete
understanding of immunological mechanisms underlying
protection against TB hampers vaccine discovery and
development. Our aim was to define host correlates of
prospective risk of TB disease following BCG vaccination.
We proposed that this knowledge would lead to greater
insight into protective mechanisms against the disease,
which, in turn, would inform vaccine development.
We applied a systems biology approach to analyze
unique prospective samples, and showed that in healthy
infants who displayed different patterns of immune res-
ponses to the BCG vaccine, distinct mechanisms may
underlie susceptibility to future TB disease, suggesting
that the same intervention may not benefit all.
Methods
Study participants, blood collection and follow-up
We enrolled infants at the South African Tuberculosis
Vaccine Initiative (SATVI) field site, near Cape Town,
South Africa. This area has a high TB disease incidence
in children < 2 years of age (>1,000/100,000/year). This
study was nested within a randomized controlled trial
(RCT) [2], which aimed to determine whether intradermal
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or percutaneous delivery of Japanese BCG at birth resulted
in equivalent protection against TB. For our correlates of
risk study, we enrolled 5,724 infants, randomly, from the
11,680 infants enrolled in the RCT, when they were
10 weeks of age, as previously described [3] (Fig. 1). The
following were exclusion criteria: mothers known to be
HIV-infected, BCG not received within 24 h of birth,
significant perinatal complications, any acute or chronic
disease in the infant, clinically apparent anemia in the in-
fant, and household contact of the infant with any person
with TB, or any person who was coughing.
At 10 weeks of age, blood was collected. Infants were
then followed for 2 years. Community-wide surveillance
systems, described for the parent study [2], identified
all children exposed to adults with TB, or children with
suspected TB disease. These children were admitted to
a dedicated case verification ward for evaluation [2]. Inves-
tigations included clinical and epidemiologic evaluation,
two induced sputa and gastric aspirates for mycobacterial
culture, chest roentgenography and a tuberculin skin test
[2]. Cases included in the current study were either culture
positive for Mycobacterium tuberculosis (primary analysis),
Fig. 1 Cohort of infants vaccinated with BCG at birth. At 10 weeks of age, blood was collected from HIV-negative, HIV-unexposed infants with no
active or chronic illnesses (including suspected TB), and with no household exposure to an adult who was coughing, or who had TB disease.
Infants were then followed for 2 years. Community-wide surveillance systems identified all children exposed to adults with TB, or children with
suspected TB disease. Among these children, “definite” TB cases were defined by presence of clinical signs and symptoms of lung disease plus a
sputum (induced, or early morning gastric aspirate) culture positive for M. tuberculosis, while “probable” TB cases were defined by absence of a
positive culture in the presence of strong epidemiological, clinical and chest roentgenographic evidence of TB disease. Two groups of controls
were identified: “household” controls were exposed to an adult in the household with TB but were found not to have TB, whereas “community”
controls were infants who were either investigated for TB and found not to have disease, or infants chosen at random from the rest of the cohort.
For functional assays, up to 29 definite cases and 110 controls (household controls, n = 55, and community controls, n = 55) were included in
different analyses. Primary analysis of transcriptional profiling was restricted to those cases and controls included in functional assay analysis for
whom PBMC were available
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or were not culture positive but there was strong clinical,
roentgenographic and epidemiological evidence of TB
disease (validation analysis). Infants who were evaluated in
our case verification ward and were found not to have TB
were included as controls (primary analysis). Some of the
control infants included in the validation analysis lived in
the same endemic area but did not meet the criteria for TB
investigation (community controls).
Human participation was according to the US Depart-
ment of Health and Human Services and good clinical
practice guidelines. This included protocol approval by
the University of Cape Town Research Ethics Committee
(reference 016/2001), and written informed consent
from the parent or legal guardians.
Gene expression analysis
PBMC isolation, storage, and in vitro incubation for RNA
isolation and amplification
Peripheral blood mononuclear cells (PBMC) were isolated
from peripheral blood of 10-week-old infants by density
gradient centrifugation and cryopreserved. Later, PBMC
were thawed, rested, and 106 cells were incubated in culture
with either BCG (Danish strain, Statens Serum Institut,
reconstituted as previously described [4]) at a multiplicity
of infection (MOI) of 0.18, or with medium alone. PBMC
were incubated for 12 h at 37 °C and 5 % CO2. Following
the incubation period, cells were harvested and RNA ex-
tracted using the QIAamp RNA Blood Mini Kit (Qiagen),
according to the manufacturer’s instructions. A median of
0.92 μg (range 0.24–1.56 μg) RNA was obtained from 106
PBMC. Extracted RNA was cryopreserved at −80 °C. Later,
RNA was thawed and a median 339 ng (range 88–595 ng)
amplified using the Illumina RNA Amplification Kit
(Ambion), as previously described [4]. The median RNA
yield after amplification was 15.3 μg (range 2.35–32.8 μg).
DNA microarray
Amplified RNA (750 ng per array) was hybridized to the
Illumina HumanRef-8 Expression BeadChip (version 2),
according to the manufacturer’s instructions. Arrays
were scanned with an Illumina bead array reader con-
focal scanner. Array data is now housed at the gene ex-
pression database repository Gene Expression Omnibus
(GEO) submission number GSE20716 [5].
Microarray data analysis
Raw Illumina probe data were exported from BeadStudio
and screened for quality. Scanned array images were
visually inspected for artifacts or mishandling. Diagnostic
plots, including density plots, box plots and heatmaps of
between-array distances, were used to assess hybridization
quality within the whole data set. One array failed quality
screening. Pre-processing and statistical analysis were
conducted using the R statistical language and various
software packages from Bioconductor (www.r-project.org,
version 3.1.2) [6]. Quantile normalization was applied,
followed by a log2 transformation. Bioconductor’s genefil-
ter package was used to filter out genes with low expres-
sion (genes retained with expression values greater than
100 or 200 units in at least two samples) and insufficient
variation in expression as measured by the interquartile
range (IQR; genes retained with IQR higher than 0.2, 0.3
and 0.4) across all samples tested.
Unsupervised clustering and class assignment analysis
Unsupervised cluster analysis was performed, using R’s
cluster package, which utilizes hierarchical clustering.
This hierarchical clustering approach has been success-
fully used to identify clinically relevant cancer sub-types
in several studies [7, 8]. PBMC were incubated with
BCG or with media alone for 12 h prior to measuring
gene expression. Expression from the unstimulated condi-
tion was subtracted from that in the BCG-stimulated
condition; unsupervised clustering was used to identify
potential sub-groups of infants. Using the genefilter pack-
age with four different filtering criteria, we selected differ-
ent numbers of probes to assess the stability of clustering:
probes retained with expression values greater than 100 in
at least two samples and IQR range in expression across
samples > 0.2 (9,878 probes), probes retained with expres-
sion values greater than 200 in at least two samples and
IQR range in expression across samples > 0.2 (7,902
probes), probes retained with expression values greater
than 200 in at least two samples and IQR range in expres-
sion across samples > 0.3 (5,306 probes), and probes
retained with expression values greater than 200 in at least
two samples and IQR range in expression across sam-
ples > 0.4 (3,077 probes). The selected probes were used as
input to test the stability and robustness of the clustering
process. Two major unchanged cluster groups of 18 (clus-
ter 1) and 15 (cluster 2) core infants were observed across
the four different pre-clustering conditions. The filtering
was performed before the unstimulated condition was
subtracted from that in the BCG-stimulated condition.
There were 11 infants with an unstable cluster member-
ship as they switched membership from cluster 1 to cluster
2 dependent upon input gene number (Additional file 1:
Figure S1). The 33 donor samples were then used to train
a two-class binary classifier using pamr, a class predic-
tion tool implemented in R, to perform a class assign-
ment for the 11 unstable infants. The 11 remaining
donors were classified, six in cluster 1 group and five in
cluster 2 group. Similar class assignment was also ob-
tained using a k-Nearest Neighbors classification algo-
rithm, with k = 3.
Identification of differentially expressed genes
Bioconductor’s limma package was used to identify
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differentially expressed genes (https://bioconductor.org/
packages/release/bioc/html/limma.html). This approach
estimates the fold change (FC) between predefined
groups by fitting a linear model and using an empirical
Bayes method to moderate standard errors of the esti-
mated log-fold changes for expression values from each
gene. The p values from the resulting comparison were
adjusted for multiple testing according to the method
of Benjamini and Hochberg [9]. This method controls
the false discovery rate (FDR), which was set to 0.05
(5 % FDR). Limma analysis was then used to identify genes
significantly differentially expressed between cluster 1 and
cluster 2 infants (5 % FDR). We also used limma to iden-
tify genes significantly differentially expressed in a one-
versus-all analysis comparing each group (cluster 1 cases,
cluster 1 controls, cluster 2 cases and cluster 2 controls)
with a pool of the three other groups.
Pathway analysis Pathway analysis was performed using
Gene Set Enrichment Analysis (GSEA), a non-parametric
annotation-driven statistical analysis method [10]. Analysis
of groups of genes encompassed into distinct signal trans-
duction or transcriptional pathways ultimately yields
greater insight into biological processes than simple explor-
ation of lists of differentially expressed genes [11, 12]. The
basic principle of GSEA is to use a list of genes ranked by
FC to determine whether a known biological pathway or
sets of individual genes are significantly enriched in one
phenotype when compared to another. To evaluate this de-
gree of enrichment the GSEA method calculates an enrich-
ment score (ES) based on the Kolmogorov–Smirnov
statistic. The statistical significance of a gene set’s ES is esti-
mated by an empirical phenotype-based permutation test
procedure. To account for multiple hypotheses testing,
GSEA normalizes the ES for each gene set to account for
variation in set sizes and calculates a FDR corresponding
to each normalized ES.
We systematically tested gene sets from the Molecular
Signatures Database (MSigDB; http://www.broad.mit.edu/
gsea/msigdb) C2 collection (c2.cp.v3.0.symbols.gmt), col-
lected from various online canonical pathways databases,
including KEGG, BioCarta, Reactome and NetPath, to
which we added a collection of immune-related gene sets
described in Chaussabel et al. [13].
An over-representation test was performed using Fisher’s
exact test. Statistical significance of p < 0.05 (5 % FDR) was
used to identify gene signature enrichment from a list of
genes selected as differentially expressed between two
groups of samples.
Whole blood intracellular cytokine assay
At 10 weeks of age, heparinized blood was collected
from all infants. One milliliter was immediately incu-
bated with BCG (1.2 × 106 organisms/mL), as previously
described [3]. Medium alone served as negative control,
while staphylococcal enterotoxin B (SEB; Sigma-Aldrich,
10 μg/mL) was used as a positive control. The co-
stimulatory antibodies anti-CD28 and anti-CD49d (BD
Biosciences, 1 μg/mL each) were added to all conditions,
as this results in enhancement of specific T cell responses.
Blood was incubated for 7 h at 37 °C. At this time, plasma
supernatants were harvested and cryopreserved at −80 °C.
Brefeldin A was then added, followed by incubation for an
additional 5 h. Cells were harvested, fixed and cryopre-
served, as previously described. Later, cells were thawed,
permeabilized, and stained for T cell surface markers and
for intracellular TNF-α, IFN-γ and IL-2, as previously de-
scribed. Frequency of CD4+ and CD8+ T cells expressing
these cytokines was detected by a LSRII flow cytometer
(BD Biosciences), using FACSDiva 6.1 software.
Soluble cytokine/chemokine measurement
Plasma was thawed once and levels of 29 cytokines/
chemokines determined with the human cytokine LINCO-
plex 29-bead array assay kit (LINCO Research, Millipore).
The following cytokines/chemokines were measured:
interleukin-1 alpha (IL-1α), IL-1β, IL-1RA, IL-2, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-10, IL-12p40, IL-12p70, IL-13, IL-15,
IL-17, soluble CD40 ligand (sCD40L), epidermal growth
factor (EGF), eotaxin, fractalkine, granulocyte-colony sti-
mulating factor (G-CSF), granulocyte-macrophage colony-
stimulating factor (GM-CSF), interferon-gamma (IFN-γ),
10 kDa interferon gamma-induced protein (IP-10),
monocyte chemoattractant protein-1 (MCP-1), macro-
phage inflammatory protein-1 alpha (MIP-1α), MIP-1β,
transforming growth factor-alpha (TGF-α), tumor ne-
crosis factor-alpha (TNF-α) and vascular endothelial
growth factor (VEGF). The manufacturer’s instructions
were followed. Fluorescence was detected using a
Luminex 100 IS machine (xMAP Technology, Luminex
Corporation), using Luminex software.
Lymphocyte proliferation assay
Cryopreserved PBMC were thawed in culture medium
(12.5 % v/v AB+ serum in RPMI) containing 10 μg/mL
DNase (Sigma-Aldrich). After washes, cells were stained
with 1 μg/mL Oregon Green (Molecular Probes) and
rested overnight at 37 °C in 5 % CO2. PBMC (2 × 10
5/
well) in 200 μL culture medium (12.5 % v/v AB serum in
RPMI) were incubated with BCG at a MOI of 0.01 for
6 days, at 37 °C in 5 % CO2. SEB (0.5 μg/mL) served as
positive control, while medium only served as negative
control. Cells were harvested with 2 mM EDTA (Sigma-
Aldrich) in PBS and stained with 1 μg/mL LIVE/DEAD
Fixable Violet Dead Cell Stain (Invitrogen). Cells were
fixed with FACS Lysing Solution (BD Biosciences)
and cryopreserved. Later, cells were thawed, washed,
and stained for 1 h at 4 °C with anti-CD3 Qdot605
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(clone UCHT1) and anti-CD8 Cy5.5PerCP (SK1), both
from BD Biosciences. Cells were acquired as described
above. Anti-mouse kappa beads (BD Biosciences), stained
with the respective fluorescent-labeled antibody, were
used to configure compensation settings.
Cytotoxic marker assay
Thawed PBMC (2 × 105 cells/well) in 200 μL culture
medium were incubated with BCG at a MOI of 0.1, at
37 °C in 5 % CO2. Controls included SEB (0.05 μg/mL)
or medium alone. After 72 h, cells were harvested,
stained with the violet viability dye, fixed and cryopre-
served, as described above. Later, cryopreserved, fixed
cells were thawed, washed, permeabilized with Perm/
Wash solution (BD Biosciences) and stained with the
following antibodies for 1 h at 4 °C: anti-CD3 Qdot605
(clone UCHT1), anti-CD8 Cy5.5PerCP (SK1), anti-
granzyme B Alexa 700 (GB11), anti-perforin FITC
(δG9; all from BD Biosciences) and anti-granulysin PE
(eBioDH2, eBioscience), acquired as described above.
Quantification of myeloid and lymphoid cell populations
in PBMC
Cryopreserved PBMC from case and control infants
were thawed and washed, and immediately stained. Cells
were stained for 30 min at 4 °C with the following anti-
bodies: CD45 FITC (clone 2D1), CD19 PE (clone HIB19),
CD3 APC (clone UCHT1; all from BD Biosciences),
CD11c PerCP-cy5.5 (clone Bu15), HLA-DR Alexa Fluor
700 (clone L243; both from BioLegend), CD14 Qdot605
(clone Tuk4) and LIVE/DEAD Fixable Violet Dead Cell
Stain (both from Invitrogen). Samples were acquired on a
LSRII flow cytometer and the analysis was performed
using FlowJo (version 9.3.1, Tree Star). The frequencies of
CD14+ monocytes, HLA-DR+ CD11c +mDC, CD3+ and
CD19+ lymphocytes were expressed as relative propor-
tions of live CD45+ leukocytes.
Analysis of non-expression data
Flow cytometric data were analyzed using FlowJo (version
8.8.4, Tree Star). Whole blood intracellular cytokine assay
was analyzed as previously described [3]. For the prolifera-
tion assay, only infants who had a frequency of Oregon
Greenlow CD8− T cells, following SEB incubation, that
was greater than the median frequency plus 3 median
absolute deviations (MAD) of the negative control, were
included in the analysis. For the cytotoxic marker assay,
results from infants who had a frequency of granzyme B-
expressing CD8+ or CD8− T cells, following SEB incuba-
tion, that was greater than the median frequency plus 3
MAD of the negative control, were included.
Cytokine data were imported directly into Microsoft
Excel for analysis, from the Luminex software. Duplicate
standard curves were generated for each cytokine from
the standards; these curves were used to calculate cyto-
kine levels. Since many analytes were already secreted at
broadly variable levels in unstimulated samples, we did
not subtract values from unstimulated samples, and we
report concentrations upon stimulation with BCG, un-
less otherwise indicated.
For univariate assessment of differences between infant
groups, a Mann–Whitney U test was performed, using
Prism (GraphPad Software, Inc.).
Results
Participants
Our systems biology approach combined unbiased tran-
scriptional profiling with hypothesis-driven characterization
of innate and T cell responses thought to be important for
TB control. Blood was collected, processed and stored at
10 weeks of age from a random 5,726 healthy infants, who
belonged to a parent cohort of infants routinely vaccinated
with BCG at birth [2] (refer to Fig. 1 for detail). During
2 years of follow-up, infants who developed pulmonary TB
were identified (cases), as well as those who did not develop
TB disease (controls) [2].
For functional assays, up to 29 definite cases and 110
controls (household controls, n = 55, and community
controls, n = 55) were included in different analyses.
Primary analysis of transcriptional profiling was re-
stricted to those cases and controls included in functional
assay analysis for whom PBMC were available. Two
groups of cases were identified: for primary analysis, in-
fants with culture positive pulmonary TB (“definite” cases,
n = 26 were included in analysis), and for validation ana-
lysis, infants with strong epidemiological, clinical and
roentgenographic evidence of TB disease, without a posi-
tive culture—the latter is the most common clinical pres-
entation of childhood TB (“probable” cases, n = 20). Two
groups of controls were identified: for primary analysis, in-
fants with household exposure to an adult with TB disease
and found not to have TB (“household” controls, n = 18),
and for validation analysis, infants similarly defined plus
infants who were either investigated for TB and found not
to have disease, or infants chosen at random from the rest
of the cohort (“community” controls, n = 25). The defini-
tion of primary and validation cohorts differed because of
limited sample sizes.
Correlates of prospective risk of TB disease could not
be identified
For transcriptional profiling, PBMC isolated at 10 weeks
of age from cases and controls were incubated with
BCG or medium alone for 12 h. RNA was extracted and
analyzed by DNA microarrays, as previously described
[4]. No difference could be shown between cases and
controls when gene expression from PBMC incubated
with medium only was subtracted from that in PBMC
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incubated with BCG (Additional file 1: Figure S2,
Additional file 2: Table S1; two genes were differentially
expressed with a nominal p value less than 0.05); neither
could differences be found when BCG-induced gene ex-
pression alone was examined independently (Additional
file 2: Table S1; 25 genes were different with a nominal p
value less than 0.05), nor when gene expression in
medium alone was examined independently (Additional
file 2: Table S1; 32 genes were different with a nominal p
value less than 0.05).
Multiple additional assays were completed to compare
cases and controls, focusing on immune activation
thought to be important for control of TB. In whole blood
incubated with BCG, there was no difference in frequency
of specific Th1 cells [3], nor release of pro- and anti-
inflammatory mediators (Additional file 1: Figure S3). In
PBMC incubated with BCG, there was no difference in
proliferation of T cells (Additional file 1: Figure S4), nor T
cell expression of cytotoxic molecules (Additional file 1:
Figure S5).
Finally, we tested whether frequencies of myeloid and
lymphoid cellular subsets in PBMC differed, because of
multiple reports of associations between ratios of these
cells and various infectious diseases and vaccination out-
comes [14–17]. No difference was shown (Additional file 1:
Figure S6).
Two distinct patterns of gene expression when cases
and controls were examined together
We hypothesized that divergent host responses following
BCG vaccination were responsible for the inability to
show correlates of risk of TB disease on a population
basis. We therefore examined gene expression of definite
TB cases and household contacts in the primary cohort.
Expression data from PBMC incubated with media alone
was subtracted from that of PBMC incubated with BCG
for 12 h. Unsupervised analysis revealed two major clus-
ters: one containing 24 infants—cluster 1—and one con-
taining 20 infants—cluster 2 (Fig. 2a, b). Clustering was
not associated with being a case or a control (Fig. 2b,
Additional file 1: Figure S2), and was stable, as altering
input gene number did not impact cluster membership
for the majority of infants (Additional file 1: Figure S1).
We found no clinical variable that differed between the
two clusters, including vaccination route, weeks of gesta-
tion, gender, ethnicity and birth weight (not shown); there
were also no experimental variables that differed, including
RNA quantity and quality (not shown); and there was no
significant difference between the time to TB diagnosis in
cluster 1 and cluster 2 case infants (data not shown).
Overall, 461 genes were differentially expressed be-
tween the two clusters (FC > 1.3 and FDR < 5 %; Fig. 2,
Additional file 3: Table S2). Differential expression of
these genes could also identify two clusters of infants in
the validation cohort of probable TB cases and commu-
nity controls (Additional file 1: Figure S7A, Additional
file 4: Table S3).
GSEA showed pathways that were unique to each
cluster. The primary cohort demonstrated enrichment
(FDR < 5 %) of gene sets associated with interferons, T
cells, cytokines and JAK-STAT signaling in cluster 1,
while gene sets associated with inflammation distinct
from those in cluster 1, plus gene sets of myeloid cells,
were enriched in cluster 2 (Fig. 2c, Additional file 5:
Table S4). Again, the validation cohort confirmed these
findings (Additional file 1: Figure S7B).
Next, we assessed whether results from hypothesis-
driven cellular and soluble marker assays used to inter-
rogate differences between cases and controls (above)
would align with the distinct gene expression pathway
findings. This was the case, as cluster 1 infants showed a
higher frequency of BCG-specific Th1 cells and greater
Th1-polarizing cytokine release, compared with cluster 2
(Fig. 2d, e).
Collectively, these results suggest that infants routinely
vaccinated with BCG vaccination at birth display two
distinct patterns of immune activation.
Clustering is independent of BCG stimulation ex vivo
Next, we wished to learn whether clustering of gene ex-
pression was dependent on antigenic stimulation. Using
expression data from PBMC from the primary cohort in-
cubated with media alone, we showed that 670 genes
were differentially expressed between cluster 1 and 2 in-
fants in the absence of antigen stimulation (Limma analysis,
FDR < 0.05 and FC > 1.3; Additional file 1: Figure S8). Using
these 670 genes, the majority of individual participants fell
into the same clusters as reported above, generated when
expression data from PBMC incubated from media alone
was subtracted from that of PBMC incubated with BCG,
with only three exceptions (Additional file 1: Figure S8).
Similarly, in the validation cohort, 3,221 transcripts were
differentially expressed (FDR < 0.05 and FC > 1.3) between
cluster 1 and cluster 2; clustering was found to be inde-
pendent of BCG antigen stimulation (data not shown).
Pathway analysis (GSEA), using results from the un-
stimulated samples, in the primary cohort showed that gene
sets representing myeloid cells and anti-inflammatory res-
ponses were prominent in cluster 1 (Fig. 3b). In contrast,
pathways commonly expressed in cluster 2 were associated
with T cells (Fig. 3b). Again, similar clustering was also
shown in unstimulated samples from the validation cohort
(data not shown).
Taken together, these findings suggest that after BCG
vaccination of newborns, underlying differences in the
two clusters exist that are independent of specific anti-
gen stimulation, and which may determine outcome of
antigen exposure.
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Distinct cellular and metabolic pathways among cases,
and among controls, from each of the two clusters
Next, to learn about the possible association of clustering
with risk of TB disease, we used pathway analysis (GSEA)
of gene expression from unstimulated samples in the pri-
mary cohort to identify pathways uniquely expressed in
each of four groups: a set of cases and controls from each
cluster (Fig. 3, Additional file 5: Table S4). Pathways
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Fig. 2 Identification of two clusters of gene expression in infants. Samples from the primary cohort of definite cases and household contacts
were examined together. a Unsupervised clustering analysis was performed as described in “Methods”, resulting in two major clusters of infants.
The heatmap shows results of supervised hierarchical clustering analysis (Pearson correlation), using genes differentially expressed between
infants belonging to the two clusters (Additional file 1: Figures S1 and S2); the normalized probe intensity obtained from PBMC stimulated with
media only was subtracted from the normalized probe intensity obtained from PBMC stimulated with BCG for 12 h. b Representation of cases
and controls among the two clusters. c Gene expression within biological pathways, identified by GSEA, that differed between cluster 1 (blue)
and cluster 2 (green). Representative GSEA pathways were ranked by FDR q value (and p value < 0.05). d Frequencies of BCG-specific CD4+ T cells
among infants from cluster 1 (blue circles) or cluster 2 (green circles). Antigen-specific cells were identified by cytokine expression following incubation of
whole blood with BCG for 12 h. Bars depict medians and IQR; the Mann–Whitney U test was used to assess differences. e Quantification of molecules
released in whole blood after a 7-h incubation with BCG. BCG-specific levels were calculated by subtracting levels in plasma from whole blood incubated
with costimulatory antibodies alone from those in BCG-stimulated blood. Bars depict medians and IQR; the Mann–Whitney U test was used to
assess differences
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associated with oxidative phosphorylation and activated
MAP kinase were uniquely enriched in cluster 1 cases,
while those of amino acid metabolism and glycolysis were
enriched in cluster 1 controls (Fig. 3, Additional file 6:
Table S5). Pathways associated with T cell activation, in-
cluding glucose metabolism, IL-7, IL-12 and ribosomal
protein translation [18, 19], were the most prominent in
cluster 2 cases (Fig. 3, Additional file 6: Table S5). We
could not identify pathways unique to cluster 2 controls
(Fig. 3, Additional file 6: Table S5). Similar patterns were
found in the validation cohort for cluster 1 cases and
controls (Additional file 1: Figure S7, Additional file 7:
Table S6), but no pathway enrichment was shown in clus-
ter 2 infants of the validation cohort.
It should be noted that in unstimulated PBMC for
both the primary and validation cohorts, myeloid and in-
flammatory gene signatures decreased upon BCG antigen
stimulation. This decline was greater in extent in cluster
1, compared with cluster 2 (Additional file 1: Figure S9);
therefore, an antigen-specific decrease in myeloid and
A
B
Fig. 3 Pathway analysis, using gene expression data from unstimulated PBMC, in the two clusters of infants. Samples from the primary cohort
were analyzed. A one group versus all other groups analysis approach was used to identify genes differentially expressed in each of the four groups,
when compared to a pool of the three other groups (Additional file 4: Table S3). Then, genes were ranked according to the moderated t test and GSEA
used to identify pathways enriched in each of the four groups. Finally, pathways uniquely and commonly expressed within each group were identified,
using a FDR adjusted p value cutoff of < 0.05. The Venn diagram (a) shows both shared and unique gene sets, which are identified in (b). Gene sets are
sized by normalized enrichment score (NES)
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inflammatory signatures is associated with a rise in Th1
cytokine release.
Together, these findings confirm different host re-
sponses in different groups of infants following BCG
vaccination, and suggest that distinct mechanisms could
underlie TB disease risk in different groups of infants.
High monocyte to T cell ratios and higher specific T cell
responses may be associated with risk of TB disease, in
one cluster
To explore whether observed differences in gene expression
were associated with relative abundance of cellular subsets
within PBMC, we quantified frequencies of myeloid cells
(monocytes and myeloid dendritic cells) and lymphoid cells
(T and B cells) with flow cytometry (Additional file 1:
Figure S6). Cluster 1 infants had higher frequencies
of CD14+ monocytes and lower frequencies of CD3+
T cells in PBMC, compared with cluster 2 infants (Fig. 4a),
which aligned with relatively higher myeloid pathway acti-
vation seen in cluster 1 (Fig. 3).
Since our sample sizes were small, we pooled the con-
trols from each cluster for further flow cytometric ana-
lyses. This was justified because only small differences in
gene expression between the two groups of controls were
shown—only seven genes were differentially expressed
(Additional file 6: Table S5); in contrast, the two
groups of cases showed 646 differentially expressed
genes (Additional file 7: Table S6). Cases in cluster 1
displayed higher monocyte to T cell ratios, compared
with the pool of controls and with cluster 2 cases
(Fig. 4b). No differences were observed for the other
cell subsets, including B cells (data not shown).
We then showed that cluster 1 cases had higher frequen-
cies of BCG-specific CD4+ T cells producing type 1 cyto-
kines (Fig. 4c), and that BCG induced greater upregulation
of granulysin and perforin (Additional file 1: Figure S10A),
compared with pooled controls. CD8+ and γδ TCR+ T cell
responses to BCG, as well as BCG-specific CD4+ and
CD8+ T cell proliferation, did not differ between groups
(Additional file 1: Figure S10B and data not shown).
A B
C
Fig. 4 Cellular phenotype and function in case and control infants from cluster 1 and cluster 2. Samples from the primary cohort were analyzed.
a Frequencies of monocytes and T cells, measured by flow cytometry (Additional file 1: Figure S6) in unstimulated PBMC from infants in cluster 1
(blue circles, n = 23) and cluster 2 (green circles, n = 18). b Comparison of the cellular phenotype of definite TB case infants from cluster 1 (red closed
circles, n = 15) and from cluster 2 (red open circles, n = 10) with that of pooled household controls (black closed circles for cluster 1, n = 8, and black open
circles for cluster 2, n = 8). CD14+ monocytes, CD3+ T cells and the ratio of monocytes divided by lymphocytes are shown. c Frequencies of CD4+ T
cells expressing either IFN-γ, IL-2 or TNF-α, or all three cytokines together, measured by intracellular cytokine staining and flow cytometry, following
whole blood stimulation with BCG for 12 h. For this analysis, definite TB case infants from cluster 1 (red closed circles, n = 12) and from cluster 2
(red open circles, n = 7) were compared to pooled household controls (black closed circles for cluster 1, n = 5, and black open circles for cluster 2, n = 8).
Bars depict medians and IQR; the Mann–Whitney U test was used to assess differences in all analyses
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These results suggest that in a major cluster of BCG
vaccinated infants, the presence of high frequencies of
monocytes, or of a specific type 1 cellular immune re-
sponse, both regarded as important for control of myco-
bacteria, might be associated with higher risk of developing
TB disease.
M2 alternatively activated and M1 classically activated
monocytes in different clusters of cases
Next, we explored gene expression pathways enriched in
different clusters of case infants in greater detail. Genes
in the M1 or M2 monocyte pathways showed an associ-
ation with ratio of myeloid to lymphoid cellular fre-
quency in case infants (Fig. 5a). Pathways in cluster 1
cases included oxidative phosphorylation, which is the
mechanism that activated anti-inflammatory monocytes,
or M2, use to gain energy for function and survival [18].
A detailed analysis revealed enrichment for expression
of genes characteristic of both M1—classically activated
monocytes—and M2 in cluster 1 cases, compared with
the other group of cases and the controls (Fig. 5b). Clus-
ter 2 cases showed enrichment of a sub-set of M1 genes
(Fig. 5b). Cluster 1 controls showed modest enrichment
of M1 genes, possibly related to higher frequencies of
monocytes observed in cluster 1 infants (Figs. 4a, 5b).
We evaluated whether whole blood production of cy-
tokines associated with M1 and M2 would follow gene
expression patterns. Production of EGF in unstimulated
blood, and of EGF, VGEF and IL-1Ra—all associated
with M2 macrophages [20]—in BCG-stimulated blood
modestly confirmed gene expression patterns (Fig. 5c).
Conversely, IFN-γ-driven expression of IP-10, typically
from M1 monocytes, was similar across groups, again sup-
porting gene expression results (Fig. 5c). Pro-inflammatory
IL-6, MIP-1α and MIP-1β, typically from M1 monocytes,
were slightly elevated in cluster 1 cases, compared with
cluster 2 cases (Fig. 5c).
These findings suggest that monocyte phenotype may
additionally contribute to differences in immunogenicity
in the two infant clusters.
Discussion
Our primary aim was to determine correlates of risk of
TB disease following BCG vaccination of newborns.
Despite combining unbiased and hypothesis-driven ap-
proaches, no such correlates could be identified. This
may be due to the observation that, on a population
level, infants vaccinated with BCG at birth demonstrated
two distinct clusters of immune response, as measured
by global transcriptional response to in vitro stimulation
with BCG. Within these clusters, infants at risk of TB
disease showed different gene expression, suggesting that
unique correlates of risk may not be found within clusters.
Our sample size was not adequate to do this analysis
definitively, but was sufficient for learning about distinct
immune responses within clusters. Immediate implica-
tions of this observation are that future studies aimed at
defining correlates of risk of, or of protection against, TB
disease should plan for adequate sample sizes to address
heterogeneity, and that analysis strategies should account
for heterogeneity.
We observed that infants with the highest or lowest
ratios of monocytes to T cells were at risk of developing
TB disease. We have also used full differential blood
count data available from study cohorts in Durban,
South Africa, to show that both high and low monocyte
to lymphocyte ratios were associated with TB disease
risk in HIV-exposed infants, post-partum mothers and
adults initiating anti-retroviral therapy [14–16]. It has
previously been shown that hematopoietic stem cells can
directly respond to IFN-γ mobilizing myeloid cells in re-
sponse to mycobacterial infections [21]. In the absence
of M. tuberculosis infection, it is therefore possible that
persistence of live attenuated BCG from vaccination at
birth may have driven myeloid cell expansion seen in
case infants with higher monocyte to T cell ratios. We
cannot exclude that host genetic determinants, other in-
fections, other immunizations, or environmental deter-
minants, such as nutrition, might also be important; we
did not find influence of other infections or environmen-
tal co-variates in our infants. Future studies will address
these variables in a systematic fashion.
We further showed that case infants with higher
monocyte to T cell ratios have a transcriptional profile
associated with an alternatively activated macrophage
phenotype (M2), modestly confirmed by soluble marker
measurement data. The M1/M2 pathways used in this
study included those defined but not yet included in the
MSigDB database [22], and pathways associated with the
development of M2 phenotype, such as activated MAP
kinase signaling and platelets [18, 23]. The latter two
functions have been shown to drive monocyte differenti-
ation into giant cells, which can suppress the mycobacteria-
specific immune response [18, 23]. We have previously
shown that healthy BCG vaccinated infants have M1
macrophage phenotype [4, 24], suggesting that the usual
host response to BCG immunization involves classically ac-
tivated monocytes (M1 activation was seen in all cases and
controls in the current study, with M2 in addition in the
case group referred to above). Typically, M1 macrophages
are associated with killing of mycobacteria, whereas M2
macrophages are associated with tissue repair and bacterial
persistence [25, 26]. Therefore, activation of M2 cells may
be involved in pathogenesis of risk of TB disease.
It is widely accepted that T cells are critical for control
of M. tuberculosis infection, and to prevent progression
to active TB disease [27–29]. The importance of CD4+ T
cells is evident in persons with HIV-1-associated depletion
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of CD4+ T cell numbers and function; while not on anti-
retroviral therapy, these individuals are at > tenfold greater
risk of progression from infection to disease [30]. Humans
with mutations of genes in the Th1 response axis are
highly susceptible to mycobacterial disease [31]. As a
consequence, IFN-γ expression has been considered as a
correlate of induced immunity, or “vaccine take”, in clinical
trials of novel TB vaccines. However, we have recently
shown that vaccine-induced antigen-specific Th1 responses
did not correlate with risk of TB disease, following BCG
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Fig. 5 Evidence of differential M1 and M2 monocyte activation in cases and controls from different clusters. Samples from the primary cohort were
analyzed. a Heatmap showing genes associated with AMPK, oxidative phosphorylation, translation, M1 monocytes and M2 monocytes, which were
differentially expressed between cluster 1 cases and the three other groups, or cluster 2 cases and the three other groups. Cases from clusters 1 and 2
are shown. To build the heatmap, the infants were first ranked by increasing expression intensity for each gene. Then, the mean-rank, across the set of
genes, for each infant was used to order infants from the lowest to the highest mean-rank. A Spearman correlation was used to assess the significance
(p value < 0.0008) of the association between the ordering of the infants and the monocyte to T cell ratio. b The p value table from an over-representation
test performed using Fisher’s exact test to identify M1 (right column) and M2 (left column) gene signature enrichment amongst up-regulated in each of the
four groups of infants. (c) Concentrations of pro- and anti-inflammatory molecules were measured by Luminex in plasma from whole blood stimulated
with BCG for 7 h. Bars depict medians and IQR; the Mann–Whitney test was used to assess differences in all analyses
Fletcher et al. BMC Medicine  (2016) 14:76 Page 11 of 13
vaccination of newborns: frequencies of BCG-specific IFN-
γ-expressing, polyfunctional (co-expressing IFN-γ, TNF-α
and IL-2) or IL-17-expressing CD4+ T cells, as well as
IFN-γ-expressing CD8+ T cells, did not correlate with risk
[3]. Surprisingly, in the current study higher frequencies of
BCG-specific Th1 and polyfunctional cells were detected
in a cluster of infants at risk of TB disease; the same infants
also had M2 monocyte activation. Together, these findings
suggest that a strong Th1 response in a context of
heightened alternative activation of monocytes may be
detrimental to the host.
Conclusions
Our findings suggest that distinct patterns of host res-
ponses to Mycobacterium bovis BCG are present in infants
vaccinated with BCG. Vaccines for intracellular pathogens
are designed to boost Th1 immune responses, which may
be an effective strategy for immune response cluster 2
infants, but may not be effective for protection of cluster 1
infants. It is tempting to hypothesize that partial efficacy
observed with candidate vaccines for TB, HIV and malaria
[32–34] can be ascribed to differential host responses
within populations. Indeed, we have shown that the mono-
cyte/lymphocyte ratio impacts on the efficacy of the malaria
vaccine RTS,S, which protects children with lower ratio
(similar to immune responses in our cluster 2), but not
higher ratio (similar to immune responses in our cluster 1)
in a phase II efficacy trial in Kilifi, Kenya [17].
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